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Neurodegenerative diseases are disabling, incurable, and progressive conditions
characterized by neuronal loss and decreased cognitive function. Changes in gut
microbiome composition have been linked to a number of neurodegenerative diseases,
indicating a role for the gut-brain axis. Here, we show how specific gut-derived bacterial
strains can modulate neuroinflammatory and neurodegenerative processes in vitro
through the production of specific metabolites and discuss the potential therapeutic
implications for neurodegenerative disorders. A panel of fifty gut bacterial strains was
screened for their ability to reduce pro-inflammatory IL-6 secretion in U373 glioblastoma
astrocytoma cells. Parabacteroides distasonis MRx0005 and Megasphaera massiliensis
MRx0029 had the strongest capacity to reduce IL-6 secretion in vitro. Oxidative stress
plays a crucial role in neuroinflammation and neurodegeneration, and both bacterial
strains displayed intrinsic antioxidant capacity. While MRx0005 showed a general
antioxidant activity on different brain cell lines, MRx0029 only protected differentiated
SH-SY5Y neuroblastoma cells from chemically induced oxidative stress. MRx0029
also induced a mature phenotype in undifferentiated neuroblastoma cells through
upregulation of microtubule-associated protein 2. Interestingly, short-chain fatty acid
analysis revealed that MRx0005 mainly produced C1-C3 fatty acids, while MRx0029
produced C4-C6 fatty acids, specifically butyric, valeric and hexanoic acid. None
of the short-chain fatty acids tested protected neuroblastoma cells from chemically
induced oxidative stress. However, butyrate was able to reduce neuroinflammation
in vitro, and the combination of butyrate and valerate induced neuronal maturation,
albeit not to the same degree as the complex cell-free supernatant of MRx0029.
This observation was confirmed by solvent extraction of cell-free supernatants, where
only MRx0029 methanolic fractions containing butyrate and valerate showed an anti-
inflammatory activity in U373 cells and retained the ability to differentiate neuroblastoma
cells. In summary, our results suggest that the pleiotropic nature of live biotherapeutics,
as opposed to isolated metabolites, could be a promising novel drug class in drug
discovery for neurodegenerative disorders.
Keywords: gut microbiota-derived bacterial strains, microbiome, neurodegenerative diseases,
neuroinflammation, neuroprotection, oxidative stress, gut-brain axis, short-chain fatty acids
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 September 2019 | Volume 13 | Article 402
fncel-13-00402 September 19, 2019 Time: 10:16 # 2
Ahmed et al. Neuroprotection by Gut Microbiota-Derived Bacterial Strains
INTRODUCTION
Neurodegenerative diseases (NDDs) such as Parkinson’s
disease (PD) and Alzheimer’s disease (AD) are disabling,
incurable disorders, often associated with aging. Progressive
and irreversible loss of neurons, neuroinflammation and
degeneration of cellular functions and structures often associated
with oxidative stress, are common features of NDDs (Habib et al.,
2018). NDDs have a profound impact on the life expectancy
of individuals and the socio-economy of the world population
(Group, 2017). In recent years, there has been mounting interest
in the gut microbiota and its interaction with the immune and
central nervous system (CNS) (Fung et al., 2017). Alterations
of the microbiota composition in neurodegenerative diseases
including PD and AD have been well documented (Gerhardt
and Mohajeri, 2018; Sun and Shen, 2018). Shifts in gut bacterial
populations, possibly due to environmental and internal
stress factors, can contribute to inflammation by altering the
production of key signaling molecules in the host. Conversely,
changes in host physiology can also affect the composition
and diversity of the gut microbiota (Hollister et al., 2014;
Fung et al., 2017).
The gut microbiota exerts important effects on brain functions
and can affect physiological processes such as host stress
responses (Cryan and Dinan, 2012; Foster and McVey Neufeld,
2013), behavior related to depression and anxiety (Foster and
McVey Neufeld, 2013) and even susceptibility to autism (Hsiao
et al., 2013; Foster et al., 2017). Gut bacteria can also exert
neuroprotective effects, for instance by producing metabolites
used by the host as neurotransmitters. About 95% of the
serotonin in the human body is produced in the digestive
tract and plays an important part in gut motor function and
digestion, as well as in various cognitive and mood disorders
(Yano et al., 2015). In mice, it has been shown that a particular
subset of gut bacteria directly stimulates synthesis and release of
intestinal serotonin (Yano et al., 2015). Germ-free mice produce
lower than normal levels of dopamine and adrenaline, two
important molecules involved in the response of the CNS to
stress (Asano et al., 2012). Many gut bacteria can produce short-
chain fatty acids (SCFAs) from dietary fiber. A reduction in SCFA
concentration in fecal samples of PD patients has been described
recently, highlighting a potential link between these metabolites
and neurological disease (Unger et al., 2016).
The vagus nerve serves as a direct communication path
between gut bacteria and the central nervous system (CNS).
Recent publications indicate that the effects of a Lactobacillus
rhamnosus strain on the CNS seem to depend on signals relayed
by the vagus nerve (Bravo et al., 2011) and that gut commensal
bacteria can influence anxiety-like symptoms in a mouse model
of colitis only if the vagus nerve remains functionally intact
(Bercik et al., 2011). The CNS and gastrointestinal (GI) tract
also communicate through humoral and cellular mediators
via the hypothalamic-pituitary-adrenal axis and the immune
system by means of cytokines, chemokines and small peptides
(De Palma et al., 2014).
Notwithstanding the different cell types and etiology
associated with NDDs, inflammation is a major contributing
factor to disease (Stephenson et al., 2018). Peripheral immune
cells can contribute to neuroinflammation through the
production of pro-inflammatory cytokines that are able to
cross the blood-brain barrier (BBB) and activate microglia cells.
Moreover, when the BBB is disrupted, the brain parenchyma can
be exposed to pathogens and immune cells (Hirsch and Hunot,
2009; Zhan et al., 2018).
Stress stimuli can increase gut permeability, which in turn
facilitates translocation of gut bacteria and immune responses
in the gut mucosa (Keita and Soderholm, 2010). Gram-negative
bacteria in the gut can release cell membrane components
such as lipopolysaccharide (LPS), which can engage Toll-
like receptor 4 (TLR4) on host cells and trigger a pro-
inflammatory response (Rakoff-Nahoum et al., 2004). Low
levels of circulating LPS can compromise both passive and
active BBB mechanisms, rendering the CNS vulnerable to
neurotoxic substances and activated immune cells from the
periphery (Varatharaj and Galea, 2017). TLR activation by
pathogen-associated molecular patterns (such as LPS) and
damage-associated molecular patterns (e.g., α-synuclein in PD)
is a dynamic process. TLR activation triggers a series of
downstream molecular pathways leading to the translocation
of NF-κB to the nucleus and culminating in upregulation of
pro-inflammatory cytokine expression. Therefore, therapeutic
interventions aimed at interfering with TLR signaling could
decrease pro-inflammatory cytokine responses leading to an
overall reduction of neuroinflammation, oxidative stress and
neuronal death (Fellner et al., 2013; Rietdijk et al., 2016).
We have identified gut microbiota strains that possess
modulatory activity on human cell biology and physiology
readouts relevant to neurodegeneration and neuroinflammation
which may then be developed as Live Biotherapeutics.
Here, we describe the in vitro characterization of two gut
bacterial strains with potential neuroprotective properties,
namely Parabacteroides distasonis MRx0005 and Megasphaera
massiliensis MRx0029, and report their ability to modulate both
neuroinflammation and barrier function in vitro.
MATERIALS AND METHODS
Cells and Reagents
Trypsin/EDTA, sterile phosphate buffered saline (PBS),
Dulbecco’s modified Eagle’s medium (DMEM with 4.5 g/L
D-glucose), Minimum Essential Medium Eagle (MEME),
Nutrient Mixture F-12 Ham, heat inactivated Foetal Bovine
Serum (FBS), L-Glutamine, penicillin, streptomycin, retinoic
acid, 4′,6-diamidino-2-phenylindole (DAPI), HPLC-grade
diethyl ether, formic acid, acetic acid, propionic acid, butyric
acid, hexanoic acid and phosphoric acid were purchased from
Sigma-Aldrich (Millipore, United Kingdom).
hIL-6 and hIL-8 ELISA kits were purchased from Peprotech
(London, United Kingdom).
HPLC-grade hexane, ethyl acetate, acetonitrile, water
and methanol, Dichloro-fluorescein diacetate (DCFDA),
BCA protein assay kit and general tissue culture plasticware
(Corning) were purchased from Fisher Scientific (Loughborough,
United Kingdom).
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HEK293 reporter cells stably expressing human TLR4 were
purchased from InvivoGen, U373 cells from Sigma-Aldrich, SH-
SY5Y cells and HT29-MTX-E12 (HT29-mtx) from the European
Collection of Authenticated Cell Cultures (ECACC, Public
Health England, Salisbury, United Kingdom).
Valeric acid, monoclonal anti-MAP2 (sc-74421) and anti-β3-
tubulin (clone 2G10, sc-80005) antibodies were purchased from
Santa Cruz Biotechnology.
Anti-β-actin antibody (ab1801) and Alexa Flour 594
conjugated Phalloidin (ab176757) were purchased from Abcam
(United Kingdom).
Bacterial Culture – Collection of
Bacterial Cell-Free Supernatants
A total of 50 proprietary bacterial strains from the 4D Pharma
Ltd., culture collection, a strain library consisting of isolates
derived from fecal samples of healthy human donors, were
grown anaerobically in Yeast Casitone Fatty Acids+ broth
media (YCFA+, E&O Labs, Scotland, United Kingdom) (Yuille
et al., 2018). Viable cell counts (VCC) were determined using
an Automated Spiral Plater (Don Whitley Scientific, Bingley,
United Kingdom) and a Protocol 3 Completed Automated
Colony Counting and Chromogenic Identification System
(Synbiosis, Cambridge, United Kingdom). Bacterial cell-free
supernatants (BCFS) were obtained from stationary phase
cultures (inoculated from an overnight culture of a subbed
colony from a streaked freezer stock) by centrifuging 10 ml of
cultures at 5000 × g for 5 min and filtering using a 0.2 µM
filter (Millipore, United Kingdom). 1 ml aliquots of the bacterial
cell-free supernatants were stored at−80◦C until use.
Preparation of MRx0005 and MRx0029
Cultures
Strains MRx0005 and MRx0029 were cultured to stationary
phase as described above in a total of 100 ml of YCFA+ media.
BCFS were prepared as described above. 20 ml aliquots of each
BCFS (untreated control) were stored at −80◦C until needed for
sequential extraction.
Sequential Solvent Extractions –
Preparation of Crude Extracts of
MRx0005 and MRx0029
Three biological replicates of MRx0005 and MRx0029 BCFSs
and YCFA+ (media control) were extracted sequentially with
HPLC-grade hexane (HEX), diethyl ether (DE), ethyl acetate
(EtOAc), acetonitrile (ACN) and methanol (MeOH). Briefly,
20 ml of BCFS were placed in glass vials and extracted at room
temperature (RT) in 20 ml of HEX on a rotary shaker (70 rpm)
for 30 min. A total of three extractions were performed on each
BCFS and YCFA+ media control. The remaining aqueous layers
were then extracted at RT in 20 ml of DE, EtOAc on a MX-RD-
Pro rotary shaker (70 rpm) for 30 min a total of three times.
The combined extracts of each sample were dried under reduced
pressure in an R-300 rotary evaporator equipped with a V-300
vacuum pump (Büchi, Flawil, Switzerland) at a temperature not
exceeding 30◦C. The resulting extracts were re-solubilized in
2 ml of corresponding solvent and aliquoted in four 1.5 ml
Eppendorf tubes (500 µl each corresponding to 5 ml of original
sample). The remaining aqueous layers were then extracted at
RT in 20 ml of DE, EtOAc on a MX-RD-Pro rotary shaker
(70 rpm) for 30 min a total of three times. The combined extracts
of each sample were dried under reduced pressure in a R-300
rotary evaporator equipped with a V-300 vacuum pump (Büchi,
Flawil, Switzerland) at a temperature not exceeding 30◦C. The
resulting extracts were re-solubilized in 2 ml of corresponding
solvent and aliquoted in four 1.5 ml Eppendorf tubes (500 µl each
corresponding to 5 ml of original sample).
The remaining aqueous layers were evaporated to dryness
using an R-300 rotary evaporator. The resulting dry extracts were
extracted for 30 min in 20 ml of ACN a total of three times.
The ACN extracts were combined, evaporated to dryness using
a rotary evaporator, resolubilised in 2 ml of ACN and aliquoted
in four 1.5 ml Eppendorf tubes (500 µl each). The remaining
dry extracts (ACN insoluble portion of the extracts) were then
extracted for 30 min in 20 ml of MeOH a total of three times.
The MeOH extracts were combined, evaporated to dryness using
an R-300 Rotary Evaporator, resolubilised in 2 ml of MeOH and
aliquoted in four 1.5 ml Eppendorf tubes (500 µl each).
Aliquots of the crude extracts were kept overnight at
−20◦C inducing the precipitation of proteinaceous components.
Following overnight precipitation, each aliquot was centrifuged
at 10,000 × g for 6 min and transferred to a new 2 ml tube.
Overnight precipitation was repeated three times after which
extracts were dried in a RVC 2-18 CDPlus speedvac (Christ,
Osterode am Harz, Germany) and weighed. All dried aliquots of
each extract were stored at−80◦C until further use.
SCFA Extraction From Bacterial
Cell-Free Supernatants
Short-chain fatty acid extraction from YCFA+, YCFA+ spiked
with a standard mix of SCFAs (40 mM acetic acid and 20 mM
formic acid, propionic acid, butyric acid, valeric acid and
hexanoic acid) as well as the methanol extracts of MRx0005 and
MRx0029 and YCFA+ (media control) was conducted according
to the method of De Baere et al. (2013).
HPLC Analysis of SCFAs
HPLC detection and quantification of SCFAs was conducted
according to the method of De Baere et al. (2013) with
slight modifications. Briefly, HPLC analysis was performed
using a Waters e2695 HPLC system equipped with a Waters
Photodiode Array (PDA) detector 2998 (Waters Limited, Elstree,
United Kingdom). HPLC analysis of SCFAs standards, SCFAs
extracted from MRx0005 and MRx0029 BCFS and MRx0005
and MRx0029 hexane, diethyl ether, ethyl acetate, acetonitrile
and methanol extracts were performed using an Xselect R© HSS
T3 3.5 µm × 4.6 mm × 150 mm LC column (Waters Limited,
Elstree, United Kingdom). The LC analysis was performed
using the photodiode array detector (PDA) set to analyse
wavelengths of 200–800 nm. SCFA detection and quantification
was performed at 210 nm. The mobile phase consisted in 25 mM
sodium phosphate buffer in HPLC water (pH adjusted to 3.0
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using phosphoric acid (A) and acetonitrile (B). The LC method
for SCFA detection and quantification was run using the solvent
system with the following gradient: t0′ A = 95%, B = 5%; t10′
A = 95%, B = 5%; t30′ A = 30%, B = 70%; t31′ A = 0%, B = 100%;
t36′ A = 0%, B = 100%; t38′ A = 5%, B = 95%; t60′ A = 5%,
B = 95%; flow = 1 ml/min.
A seven-point calibration curve was prepared for each SCFA
by injecting 20 µl of a two-fold serial dilution of a SCFA (40 mM
acetic acid and 20 mM formic acid, propionic acid, butyric acid,
valeric acid and hexanoic acid). Qutification- extraction efficiency
was calculated using the formula below:
[SCFA in YCFA+ spiked and extracted]/[SCFA in YCFA+
spiked not extracted]
Extraction efficiency was used to determine the concentrations
of individual SCFAs in each sample. The production of
specific SCFAs was calculated by subtracting the amount of
corresponding SCFA present in the unspiked media control.
Targeted Metabolomics: Bacterial
Metabolites and Fatty Acid Analysis
Sample analysis was carried out by MS-Omics (Copenhagen,
Denmark). A mixed pooled sample (QC sample) was created by
taking an aliquot from each sample. This sample was analyzed
with regular intervals throughout the sequence. Matrix effects
were tested for quantified compounds by spiking the QC sample
in a minimum of two levels.
For GC-metabolite analysis, samples were derivatized
with methyl chloroformate using a slightly modified
version of the protocol described by Smart et al. (2010).
All samples were analyzed in a randomized order. Analysis
was performed using GC (7890B, Agilent) coupled with
a quadrupole detector (59977B, Agilent). Raw data was
converted to netCDF format using Chemstation (Agilent),
before the data was imported and processed in Matlab R2014b
(Mathworks, Inc.) using the PARADISe software described by
Johnsen et al. (2017).
For SCFA analysis, samples were acidified using hydrochloric
acid, and deuterium-labeled internal standards were added.
Analysis was performed using a high-polarity column (ZebronTM
ZB-FFAP, GC Cap. Column 30 m × 0.25 mm × 0.25 µm)
installed in a GC (7890B, Agilent) coupled with a quadrupole
detector (59977B, Agilent). Raw data was converted
to netCDF format using Chemstation (Agilent), before
the data was imported and processed in Matlab R2014b
(Mathworks, Inc.) using the PARADISe software described by
Johnsen et al. (2017).
Quantification of Bacterial Indole
Production From L-Tryptophan
Bacterial Indole production was quantified using an assay
described previously (Sasaki-Imamura et al., 2010). Bacteria
were cultured to stationary phase of growth. 0.5 mM indole
in YCFA+ media was used as a positive chemical control in
this assay. The Indole assay was performed using 24-well (non-
treated) assay plates. 100 mM tryptophan solution in HCl
was dispensed into each well to give a final concentration of
6 mM. 1 ml stationary phase bacterial culture was added to
each well and incubated for a further 48 h. Assay plates were
centrifuged at 3,500 × g at RT for 10 min. The supernatant
was retained, and the pellet discarded. In a 96-well plate 140 µl
supernatant was dispensed in triplicate. 140 µl Kovac’s reagent
was added and the absorbance read at 540 nm using a BioRad
iMark microplate absorbance reader. The standard curve was
prepared by plotting absorbance as a function of final Indole
concentration (mM). Indole concentration of the test sample was
calculated using the equation extrapolated from linear regression
of the standard curve.
2,2-Diphenyl-1-Picrylhydrazyl (DPPH)
Free-Radical Assay
BCFS were thawed at 4◦C for approximately 2 h prior to
use. All samples were diluted 1:2 in 1.5 ml microfuge tubes
using sterile 5 mM PBS pH 7 yielding a final volume of 1 ml.
A stock solution of 500 µM Trolox in 5 mM PBS, pH 7
was prepared to make the standard curve. Lazaroid antioxidant
U83836E was included (200 µM in 100% methanol) as a positive
control. The DPPH assay was performed in a 96-well plate as
described previously (Chai et al., 2012) with minor modifications
made. In brief, 10 µl sample/standard/control was added, in
triplicate, to corresponding wells of a 96-well plate. 200 µl
of a 200 µmol/L DPPH solution was added to three empty
wells as a control. 190 µl of 200 µmol/L DPPH was added to
sample/standard/control wells and plates incubated in the dark
for 30 min at RT. Absorbance was read at 515 nm using a BioRad
iMark microplate absorbance reader. DPPH radical scavenging
activity was calculated as follows:
DPPH radical scavenging activity (%)
= [1− (Asample − Ablank)/Acontrol)] × Dilutionfactor × 100
where Asample was the average absorbance of
sample+ 200 µmol/L DPPH, Acontrol was the average absorbance
of methanol DPPH without sample, and Ablank is the average
absorbance of YCFA± media blank.
2,2′-Azino-Bis-3-Ethylbenzthiazoline-6-
Sulfonic Acid (ABTS) Assay
The total antioxidant capacity assay was performed using
the Antioxidant Assay Kit according to the manufacturer’s
instructions. Briefly, all samples were diluted 1:4 in 1X assay
buffer. In a 96-well plate, 10 µl standard/control/sample was
added in triplicate. 20 µl myoglobin working solution was
added to all standard/control/sample wells. 150 µl ABTS
substrate solution was added to each well and the absorbance
measured at 405 nm using a BioRad iMark microplate
absorbance reader.
Bacterial Cell-Free Supernatants Used in
Cell-Based Assays
10% v/v of BCFS was used throughout all the cell-based assays
presented in this study. During the assay development stage,
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a range of YCFA+ volumes across all assay platform was tested
for interference. At 10% v/v, YCFA+ media did not affect per
se the different biochemical and cellular read-outs. YCFA+,
the bacterial growth media considered our blank, is a rich
media containing amino-acids, vitamins and SCFAs, so it is
expected to interfere at some level with biochemical and cellular
assays. Moreover, the results from metabolomics analysis further
support the use of 10% v/v as the right compromise to allow
a clear appreciation of the effects attributable to the different
bacterial metabolites. A concentration of BCFS higher than 10%
v/v would have altered the pH of the culture media with dramatic
effects on cell viability or would have overly activated the cells in
our in vitro assays.
Reporter Assay for HEK-Blue hTLR4
HEK293-Blue reporter cells stably expressing human TLR4
(HEK-TLR4), were cultured according to the manufacturer’s
instructions. Briefly, HEK-TLR4 cells were maintained in
DMEM 4.5 g/L D-glucose supplemented with 10% (v/v) heat-
inactivated FBS, 4 mM L-Glutamine, 100 U/ml penicillin,
100 µg/ml streptomycin, 100 µg/ml normocin, 1X HEK-Blue
selection media.
Briefly, cells were washed with PBS, dissociated in PBS and
collected in growth media. Cells were plated in 96-well plates at
a density of 25,000 cells/well. To evaluate the effect of bacteria
strains on LPS inducing NF-κB promoter activation, cells were
treated with 10 ng/ml LPS in presence or absence of 10%
supernatants and incubated in a CO2 incubator. Treatments
proceeded for 22 h at 37◦C and 5% CO2, after which the detection
of Secreted Embryonic Alkaline Phosphatase (SEAP) activity
from cell culture supernatant was performed using QUANTI-
blue solution according to manufacturer’s instructions. Briefly,
20 µl of cell-free supernatant was collected and analyzed for
the presence of SEAP by mixing with 200 µl of sterile-filtered
QUANTI-Blue detection media. After 2 h incubation at 37◦C,
optical density was measured at 655 nm on a microplate reader
(iMark microplate, Bio-Rad).
U373 Cell Treatment
U373 is a human glioblastoma astrocytoma cell line. Cells
(passage 20th–37th) were maintained in 25 ml MEME
supplemented with 10% heat-inactivated FBS, 4 mM
L-Glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin
and 5 µg/ml plasmocin, 1% Non-Essential Amino Acids, 1%
Sodium Pyruvate (referred to throughout as full growth media).
Cells were plated in 24-well plates at a density of 100,000
cells/well in 1 ml of full growth media and left to rest at 37◦C
and 5% CO2 for 72 h.
BCFS Treatment
On the day of the treatment, the media was removed from
each well, cells were rinsed with 0.5 ml wash media (serum free
MEME), 0.9 ml stimulation media (MEME media containing
2% FBS) containing 1 µg/ml LPS was added to the appropriate
wells and incubated at 37◦C and 5% CO2. After 1 h pre-
incubation, cells were removed from CO2 incubator and
treated with 100 µl bacteria supernatant. Media control was
used as control.
SCFA Treatment
Cells were pre-treated for 1 h with 1 µg/ml LPS indicated
above and incubated at 37◦C and 5% CO2. After 1 h pre-
incubation, cells were removed from CO2 incubator and treated
with increasing concentration of fresh prepared Sodium Butyrate
(SB), Sodium Valerate (SV) and Hexanoic Acid (HA).
MRx0005 and MRx0029 Fraction Treatment
Cells were pre-treated for 1 h with 1 µg/ml LPS as indicated
above. Afterward, cells were removed from CO2 incubator and
treated with 100 µl of the different fractions. Fractions from
media were used as controls.
Following each treatment, cells were incubated for 24 h
incubation at 37◦C and 5% CO2. Afterward cell-free supernatants
were collected and centrifugated at 10,000 × g at 4◦C for 3 min.
Samples were aliquoted in 1.5 ml microtubes and stored in
−80◦C for hIL-6 and hIL-8 ELISA.
HMC3 Cell Treatment
Human microglia HMC3 cells were grown in glutamine-
supplemented EMEM media containing 15% heat inactivated
FBS and 100 U/ml penicillin and 100 µg/ml streptomycin. HMC3
cells were plated in 24 well plates at a density of 50,000 cells/well.
Cells were left in CO2 incubator to rest for 48 h. The cells were
then washed in blank EMEM and pre-treated in 2% FBS growth
media with 10 ng/ml TNF-α for 1 h. Thereafter 10% cell-free
bacterial supernatants for MRx0005 and MRx0029 stationary
growth cultures were added to TNF-α-treated and untreated wells
and incubated in CO2 incubator at 37◦C for 24 h. Cell-free
supernatants were collected and centrifugated at 10,000 × g for
3 min and 4◦C. Samples were aliquoted in 1.5 ml microtubes and
stored in−80◦C for hIL-6 and hIL-8 ELISA.
Measurement of IL-6 and IL-8 From U373
and HMC3 Cells
Secretion of IL-6 and IL-8 was analyzed using hIL-6 and hIL-8
Standard ELISA Kits, according to the manufacturer’s protocol
in the cell-free supernatants from U373 and HMC3 cells treated
as described above. Samples were measured at 405 nm with
correction wavelength set at 655 nm on a microplate reader
(iMark, Bio-Rad). Raw data were plotted and analyzed using
GraphPad Prism 7 software. The hIL-6 ELISA development
kit allows the quantitative measurement of human IL-6 within
the range of 24-1500 pg/ml, while hIL-8 ELISA kit the range
is 15.6-1000 pg/ml.
ROS Measurement in U373, HMC3, and
SH-SY5Y Cells
To evaluate ROS production, U373 cells and HMC3 were plated
in black 96 well plates at a density of 10,000 cells/well. U373
cells were rested for 72 h while HMC3 were left to rest for
48 h. Cells were washed with pre-warmed PBS and stained with
10 µM DCFDA molecular probe for 20 min in growth medium
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containing 2% FBS. Afterward, the cells were washed with pre-
warmed PBS again and treated with 100 µM TBHP in the
presence or absence of 10% BCFS for 2 h.
Neuroblastoma SH-SY5Y cells were grown in 50% MEM
and 50% Nutrient Mixture F-12 Ham media supplemented
with 2 mM L-Glutamine, 10% heat-inactivated FBS, 100 U/ml
penicillin and 100 µg/ml streptomycin. Cells were plated in
growth medium on a black 96-well plates at 5,000 cells/well
and placed in CO2 incubator. After 24 h, media was replaced
with differentiation medium (growth medium containing 1%
FBS) and 10 µM retinoic acid (RA). Differentiation medium was
replaced every other day and cells were used after 10 days of
differentiation. On Day 10, cells were washed with pre-warmed
PBS and stained with 10 µM DCFDA molecular probe for 20 min
in growth medium containing 1% FBS. Then, cells were washed
with pre-warmed PBS again and treated with 100 µM TBHP in
the presence or absence of 10% BCFS for 2 h. After the different
treatments, plates were examined under light microscope for
obvious changes in cell morphology (e.g., round cells, irregular
shape, cell detachment). No dramatic changes in the morphology
were observed in any of the cell lines used.
Fluorescence intensity was measured using a TECAN plate
reader at Excitation 485 nm/Emission 530 nm. Raw data were
plotted and analyzed using GraphPad Prism 7 software.
Gene Expression in SH-SY5Y Cells
SH-SY5Y were plated in 6-well plates at a density of 0.5 × 106
cells. After 24 h, cells were treated in differentiation medium
(growth medium containing 1% FBS without RA) with 10% BCFS
or YCFA+ or 10 µM RA for 24 h. Thereafter, representative
images were taken using a phase contrast EVOS XL core
microscope at 40×/0.65 magnification. Cells were collected, and
total RNA was isolated according to the RNeasy mini kit protocol
(Qiagen). cDNA was made using the High Capacity cDNA
reverse transcription kit (Applied Biosystems). Gene expression
was measured by qPCR. GAPDH was used as internal control.
Fold change was calculated according to the 2−11Ct method.
Primer sets are listed in Supplementary Table S1.
Immunolabelling and Cell Imaging in
SH-SY5Y Cells
Cells were seeded onto 8-well chamber slides (Marienfeld
Laboratory Glassware) at 5× 104 cells/well overnight and treated
with 10% BCFS for 24 h. Afterward, cells were fixed with 4%
paraformaldehyde in PBS (pH 7.3) for 20 min at RT. Fixed cells
were washed with PBS, and permeabilized with 1% Triton X-
100 in PBS for 10 min. After washing with PBS, the slides were
incubated with blocking buffer (4% BSA/PBS) for 1 h at RT before
adding anti-MAP2 antibody or β3-tubulin antibodies diluted in
1% BSA/PBS for 1 h at 4◦C. They were then washed twice with
PBS, followed by incubation with Alexa Fluor-488 conjugated
anti-mouse antibody and Alexa Fluor-594 conjugated Phalloidin
for 1 h at RT. After washing 3X with PBS, slides were labeled with
DAPI and mounted with Vectashield R© (Vector Laboratories).
Slides were viewed using an Axioskop 50 microscope (Zeiss)
equipped with a 63×/1.2 W Korr objective and filter sets suitable
for detection of the fluorochromes used. Manual exposure times
for the digital acquisition of images immuno-labeled with MAP-2
were kept constant allowing comparison between different wells
and treatments. Phalloidin (F-actin) and DAPI (nuclei) exposure
times varied to suit the field of view. Randomized fields of view
were acquired using a QImaging camera controlled by Image
Pro Plus software. Images were saved as TIFF files and opened
in Adobe Photoshop CC 2015.1.2. Images of MAP2, DAPI and
Phalloidin were then overlaid and merged. Representative images
were selected to illustrate the differences in abundance and
location of the proteins examined.
Immunoblotting in SH-SY5Y Cells
SH-SY5Y cells were cultured under the indicated conditions
described above, treated with MRx0005 and MRx0029 for
24 h and lysed in RIPA buffer containing a cocktail of
protease inhibitors (Roche Diagnostics, United Kingdom).
Protein concentration was estimated using the BCA protein
assay kit, separated by SDS-PAGE and transferred to a PVDF
membrane. Membranes were then blocked with 5% non-fat
dry milk or 5% BSA and incubated overnight at 4◦C with the
primary antibodies (MAP2 and β3-tubulin, respectively). The
blots were then incubated with the appropriate horseradish
peroxidase (HRP)-conjugated secondary antibody, and proteins
were detected by chemiluminescence detection kit (Pierce
Biotechnology, Rockford, IL, United States). For both MAP2 and
β3-tubulin, β-actin served as a control to monitor protein loading
variability amongst samples.
Statistical Analysis
Normally distributed data are presented as mean ± SEM; One-
way Anova (Sidak’s multiple comparison test) was used to analyse
the data presented in this paper. A p value < 0.05 was deemed
significant in all cases.
RESULTS
In vitro Cytokine Modulation After
Exposure of a Glioblastoma Astrocytoma
Cell Line to Different Bacterial Strains
As neuroinflammation plays a pivotal role in neurodegenerative
diseases (NDDs), the stationary phase bacterial cell-free
supernatants (BCFS) of 50 bacterial strains from our proprietary
MicroRx (MRx) culture collection were screened for their
capacity to induce an anti-inflammatory response in the
U373 glioblastoma astrocytoma cell line after treatment with
lipopolysaccharide (LPS). After 24 h of treatment, secretion of the
pro-inflammatory cytokine IL-6 was measured by ELISA. U373
cells secreted a significant amount of IL-6 in response to LPS
in the presence of 2% serum, which provides the soluble form
of CD14, the co-receptor for TLR4 (Flo et al., 2002) (Figure 1).
Out of the fifty strains tested, MRx0005 (a P. distasonis strain)
and MRx0029 (a M. massiliensis strain) displayed the strongest
reduction of IL-6 in U373 cells after treatment with LPS
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FIGURE 1 | Differential mode of action between MRx0005 and MRx0029: implication for neuroinflammation. U373 cells were pre-treated with 1 µg/ml LPS followed
by 10% bacterial cell-free supernatants (BCFS) or media alone. Cell-free supernatants were collected 24 h after treatment from U373 cells and secretion of IL-6 was
measured by ELISA. Data are mean ± SEM (n = 2) (A). U373 cells were treated with 1 µg/ml LPS followed by 10% BCFS from MRx0005 and MRx0029 and
secretion of IL-6 (B) and IL-8 (C) measured by ELISA. Controls included also cells treated with BCFS alone. Data are mean ± SEM (n = 5 for IL-6, n = 4 for IL-8).
HMC3 cells were pre-treated with TNF-α and then with 10% BCFS from MRx0005 and MRx0029 or media alone for 24 h and IL-6 (D) and IL-8 (E) measured by
ELISA. Controls included also cells treated with BCFS alone. Data are mean ± SEM (n = 3). (F) HEK-Blue hTLR4 cells were treated with 10 ng/ml LPS in the
presence of 10% BCFS from MRx0005 and MRx0029 or media as control. Controls included also cells treated with BCFS alone. After 22 h, NF-κB-induced SEAP
activity was measured using QUANTI-Blue at 655 nm. Data are mean ± SEM (n = 5).
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(Figure 1A) and were therefore selected for further investigation
of their potential neuroprotective profile.
In vitro Cytokine Modulation of Multiple
Brain-Derived Cell Lines After Exposure
to MRx0005 and MRx0029
U373 cells were again treated with LPS, and secretion of IL-6
and IL-8 was measured. BCFS from stationary phase cultures
of both MRx0005 and MRx0029 significantly down-regulated
the production of IL-6 in U373 cells pre-treated with LPS
(Figure 1B). Although not significant, MRx0029 alone slightly
increased the basal level of IL-6 compared to the media alone.
Interestingly, a different signature for the two strains was
observed for IL-8 secretion by U373 cells. MRx0005 decreased
the amount of LPS-induced IL-8, while only negligible levels
of IL-8 were produced in the absence of LPS (Figure 1C).
On the contrary, MRx0029 induced higher IL-8 secretion than
the respective controls, both alone and after LPS challenge
(Figure 1C). As activation of microglia represents a prominent
feature in neuroinflammation associated with several NDDs,
human immortalized microglial clone 3 (HMC3) cells were
exposed to LPS or TNF-α to induce secretion of proinflammatory
cytokines such as IL-6 and IL-8 (Dello Russo et al., 2018),
however, TNF-α was used in subsequent experiments as it gave
a higher response than LPS (Figures 1D,E). Neither MRx0005
nor MRx0029 reduced the production of IL-8 (Figure 1E). Of
note, MRx0005 had only a marginal effect in this in vitro model
of neuroinflammation, while MRx0029 significantly reduced IL-
6 secretion in TNF-α-treated HMC3 cells. Interestingly, neither
strain induced IL-6 secretion per se (Figure 1D) and again
MRx0029 alone induced IL-8 secretion, as shown in U373
cells (Figure 1E).
Inhibition of NF-κB Promoter Activation
by MRx0005 and MRx0029
TLR4 is expressed by glial cells and binds LPS, to promote a
cascade of events that culminates in activation of transcription
factors including NF-κB and pro-inflammatory gene induction.
To verify whether treatment with either strain would be
able to interfere with NF-κB-Ap1 promoter activity induced
by engagement of TLR4, HEK-TLR4 cells were treated with
MRx0005 and MRx0029 alone or in combination with LPS.
Both MRx0005 and MRx0029 significantly inhibited NF-κB-Ap1
promoter activation induced by LPS (Figure 1F). Interestingly,
MRx0029 induced NF-κB-Ap1 promoter activation on its
own, but MRx0005 did not (Figure 1F), thus suggesting
that, although both strains are gram-negative bacteria, either
MRx0005 interferes with the LPS signaling pathway, or a low
amount/chemically different LPS is produced/shed by this strain.
Antioxidant Capacity of MRx0005 and
MRx0029
Bacteria can produce several antioxidant compounds as primary
and secondary metabolites. To capture the synergistic and
redox interactions among the different molecules present in the
bacterial supernatants, we used three biochemical assays aimed at
characterizing their antioxidant potential: the indole production
assay, the total radical-trapping antioxidant parameter (TRAP)
using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay and the
Trolox equivalent antioxidant capacity (TEAC) assay.
Indole derivatives are known for their antioxidant and
cytoprotective activity (Estevao et al., 2010). The indole test
is used to determine the ability of an organism to convert
the amino acid tryptophan to form indole. The free-radical
scavenging ability of antioxidants can be predicted from
standard one-electron potentials by evaluating the capacity of
an antioxidant to reduce an oxidant through color change. The
TEAC assay measures the antioxidant capacity of a compound or
a mixture of compounds.
Although both strains displayed clear indole-forming
capacity, MRx0029 production was significantly higher than
MRx0005 (0.3 and 0.2 mM, respectively, Figure 2A). The same
trend was observed in relation to the ability to act as a radical
scavenger in the DPPH assay and the total antioxidant capacity
when compared to the lazaroid antioxidant molecule U83836E, a
potent inhibitor of lipid peroxidation, or to a standard solution
of Trolox, a water-soluble antioxidant derivative of Vitamin E
(Figures 2B,C). Indeed, both strains showed anti-scavenging
and antioxidant capacity, although MRx0029 performed
better than MRx0005.
Neuroprotection From Oxidative Stress
by MRx0005 and MRx0029 Is Cell-Type
Dependent
In parallel to the evaluation of the antioxidant activity of
MRx0005 and MRx0029, we evaluated the ability of these strains
to protect U373, HMC3 and retinoic acid (RA)-differentiated
SH-SY5Y cells from reactive oxygen species (ROS) generated
by treatment with Tert-Butyl Hydrogen Peroxide (TBHP).
MRx0005 protected HMC3 and, albeit only partially, U373 cells
from TBHP-induced ROS, while MRx0029 not only showed no
protection, but appeared to slightly increase ROS production
(both results were not statistically significant, Figures 2D,E).
However, in differentiated SH-SY5Y cells, which recapitulate
most of the features of neurons in vitro, both MRx0005
and MRx0029 treatment resulted in significant protection
from ROS induced by TBHP (Figure 2F). These results
suggested a cell preference of MRx0029 in protecting cells
from hydrogen peroxide-induced ROS cytotoxicity involved in
neuroinflammation and neurodegeneration.
MRx0029 Induces a Neuron-Like
Phenotype in Undifferentiated SH-SY5Y
Cells
Interestingly, treatment of undifferentiated SH-SY5Y cells with
MRx0029 BCFS induced a differentiated phenotype after
24 h, as depicted in Figure 3A. MRx0029 treatment induced
morphological features similar to those of cells treated with
RA, a chemical commonly used for terminal differentiation
of neuroblastoma cells. Qualitative cellular evaluation using
bright-field phase-contrast microscopy showed that treatment
with MRx0029 indeed altered the morphology of the cells.
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FIGURE 2 | Antioxidant capacity of MRx0005 and MRx0029: Implication for neuro-protection. MRx0005 and MRx0029 bacteria were grown to stationary phase.
Biochemical assays were performed as described in section “Material and Methods.” (A) Indole concentration (mM); (B) DPPH scavenging activity assay reported as
percentage related to positive control compound U83836E; (C) Total antioxidant capacity relative to Trolox concentration (mM). Each value in the graph represents
the mean of three experiments corresponding to three cultures of MRx0005 and MRx0029. Data are mean ± SEM (n = 3). (D) U373 cells, (E) HMC3 cells, and (F)
differentiated SH-SY5Y cells were stained with DCFDA probe, then treated with 10% BCFS from MRx0005 and MRx0029 or media in the presence of TBHP for 2 h,
followed by measurement of fluorescence intensity at Ex/Em = 485/530 nm. Data are mean ± SEM (respectively n = 4, n = 3, and n = 4).
Cell bodies appeared larger and were more elongated than
untreated cells, with neurite processes branching out to
network with neighboring cells (Figure 3A). To further
characterize the observed phenotype of MRx0029-treated cells,
we investigated the expression of genes associated with neuronal
differentiation, such as microtubule-associated protein 2 (MAP2)
and synaptophysin (SYP). qPCR analysis revealed that MAP2
transcript was upregulated only by MRx0029. Both MRx0005
and MRx0029 slightly upregulated SYP when compared to
untreated control, but not when compared to media alone.
Media per se significantly upregulated expression of SYP in
undifferentiated SH-SY5Y.
As MAP2 gene expression was upregulated solely by MRx0029
treatment (Figure 3B), we investigated whether this was reflected
at protein level and how its cellular distribution in SH-
SY5Y cells was affected (Figures 3C,D). To this end, we first
performed immunofluorescent labeling of undifferentiated SH-
SY5Y cells treated with MRx0005, MRx0029 and media and
semi-quantified these results by Western blot analysis. As shown
in Figure 3C, MAP2 staining was increased in MRx0029-treated
cells compared to MRx0005 or media-treated cells. The staining
was localized both in the cytoplasm and along the length of
the extended neurites (Figure 3C panel c, yellow arrows). This
pattern was also revealed with the use of another MAP2 antibody
(data not shown). Western blot analysis further confirmed and
semi-quantified the MAP2 upregulation induced by MRx0029
(Figure 3D). Since MAP2 is considered a marker of terminal
neuronal differentiation, the results implied that MRx0029
induces neuronal differentiation in SH-SY5Y cells. Two more
lines of evidence supported this notion. The staining pattern of
Phalloidin in MRx0029-treated cells revealed rearrangement of
the cytoskeleton with loss of flattening morphology, large cell
bodies and small actin fibers and appearance of long extended
neurites, enlarged growth cones and sprouting of minor neurites.
Secondly, the appearance of nuclear condensation in some of
the cells treated with MRx0029 (Figure 3C, panels C and F)
were indicative of the pro-apoptotic phase associated with the
terminal differentiation process which the cells were undergoing.
We also examined the expression of the pre-terminal neuronal
differentiation marker β-tubulin. Immunofluorescent labeling of
SH-SY5Y cells treated with MRx0005 and MRx0029 showed an
increase in staining over media-treated cells (Figure 3C, Panel
G-L). However, at the protein level there was no statistical
difference between the two strains (Figure 3E), even though
MRx0029 appeared to have a higher expression level than media-
treated cells.
Distinct Metabolic Signatures of
MRx0005 and MRx0029 Associated With
Neuroprotective Phenotypes
Non-digestible carbohydrates are fermented by some members
of the gut microbiota to metabolites, such as short-chain fatty
acids (SCFAs), medium-chain fatty acids (MCFAs), succinate
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FIGURE 3 | MRx0029 induced SH-SY5Y cells differentiation. Undifferentiated
SH-SY5Y cells were treated with 10% MRx0005, MRx0029, media, 10 µM
RA for 24 h. (A) Representative images using phase contrast microscope to
show differences in morphology. Magnification 400×. Scale bar = 10 µm
(B) Treated cells as described above were collected, total RNA isolated for
qPCR to quantify MAP2 and SYP gene expression. Data are mean ± SEM
(n = 3). (C) (a–c) Representative images of immunolabelled cells with
Phalloidin (red) and MAP2 (green), (d–f) and merged with DAPI (blue) images;
(g–i) β3-tubulin immunolabelled cells (green) and (j–l) merged with DAPI (blue)
images. Magnification 630×. Scale bar = 5 µm. (D,E) Western blot analysis of
effects of MRx0005 and MRx0029 treatment on SH-SY5Y cells. Western blot
membranes were probed with antibodies to (D) MAP2 and (E) β3-tubulin.
Actin was used as a loading control. Lower panels: representative blots from
one of five separate experiments; upper panels: relative densitometric
intensity. Data are mean ± SEM (n = 5).
and lactate (Morrison and Preston, 2016), that can directly
influence the host response to neuroinflammation, oxidative
stress and cell-to-cell communication (Marcobal et al., 2013).
As both MRx0005 and MRx0029 are fermentative anaerobes, we
investigated whether we could identify specific metabolites from
the BCFS of these strains that could be related to neuroprotection
or neuroinflammation.
Fatty acid analysis, using targeted metabolomics, revealed
an interesting dichotomy in the two strains: MRx0005 mainly
produced acetic and propanoic acid (C2-C3), while MRx0029
produced butanoic (butyric), pentanoic (valeric) and hexanoic
(caproic) acid, both in the linear and branched forms (C4-
C6) (Figure 4A). Moreover, MRx0005 was found to produce
high levels of succinic acid, a dicarboxylic acid with multiple
metabolic activities, while the ratio of 4-hydroxy-phenylacetic
acid:media was higher in MRx0029 BCFS than in MRx0005
(Figure 4B). Representative HPLC chromatograms for SCFA
standards, media alone, MRx0005 and MRx0029 are reported
in Figure 4C. HPLC analysis of BCFS was used to monitor
the production of formic, acetic, propionic, butyric, valeric, and
hexanoic acid (based on retention time and absorbance spectrum
of relevant SCFAs) by MRx0005 and MRx0029. Representative
chromatograms for SCFA standards overlaid to MRx0005 and
MRx0029 BCFS extracted for SCFAs are reported in Figure 4C.
HPLC analysis confirmed the production of acetic and propionic
acid by MRx0005 and the production of butyric, valeric and
hexanoic acid by MRx0029.
Effect of SCFAs on Neuroinflammation
and Neurodifferentiation
To investigate the role of SCFAs in reducing secretion of IL-6,
U373 cells were treated with increasing concentrations of sodium
butyrate (SB), sodium valerate (SV) and hexanoic acid (HA).
The concentrations tested covered the range of concentrations
measured in the BCFS for the different fatty acids and took
into account the fact that only 10% of the above-mentioned
supernatants was used in the cell-based assays. Interestingly, only
SB inhibited LPS-induced secretion of IL-6 in U373 cells in a
concentration-dependent manner (Figure 5A). Moreover, both
SB and SV increased LPS-induced secretion of IL-8 in the same
cells (Figure 5B), suggesting that the presence of both these
SCFAs likely contributed to IL-8 induction when MRx0029 was
added to the culture (Figures 5A,B). HA did not inhibit IL-6
or IL-8 secretion after challenge with LPS. None of the SFCAs
tested induced per se secretion of IL-6 and IL-8 above the basal
level (untreated cell control). In fact, only SB (at the highest
concentration tested) decreased the basal level of IL-6 but not
IL-8 (Figures 5A,B). The reconstituted mixture of the three
SCFAs reproduced the biological activity of MRx0029 cell-free
supernatant, both in the presence and absence of LPS.
To understand whether SCFAs were also involved in
neuroprotection, differentiated SH-SY5Y cells were treated with
TBHP in the presence or absence of SB, SV and HA. Interestingly,
none of the SCFAs tested was able to protect differentiated SH-
SY5Y cells from ROS (Figure 5C), suggesting that other classes
of metabolites produced by our strains are responsible for their
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FIGURE 4 | Difference in metabolites produced by MRx0005 and MRx0029. Bacteria were grown to stationary phase and processed as described in section
“Materials and Methods.” YCFA+ was processed alongside MRx0005 and MRx0029. Authentic chemical standards were compared to retention time and mass
spectra for the identified metabolites and/or based on library matching of the acquired MS spectra with the NIST library. Only metabolites that differed between the
two strains are reported in this figure. (A) SCFA and MCFA profile (mM). (B) Succinic acid (mM) and 4-hydroxy-phenyl acetic acid (ratio sample/media). The data
presented in (A,B) are from one experiment (n = 1). (C) Representative chromatograms for MRx0005 (left panel in blue) and MRx0029 (right panel in red) overlaid to
a standard mix of SCFAs and MCFAs (Formic acid 10 mM, Acetic acid 20 mM, Propionic acid 10 mM, Butyric acid 10 mM, Valeric acid 10 mM, and Hexanoic acid
10 mM in black).
antioxidant activity on neuron-like cells. We also investigated
whether SB, SV and HA were able to induce a mature phenotype
in undifferentiated neuroblastoma cells. Indeed, butyrate and
partially valerate exerted an activity in upregulating MAP2 gene
expression in SH-SY5Y cells (Figure 5D), albeit not reaching
the same fold-change shown for MRx0029 cell-free supernatant
(Figures 3B, 5G). As butyrate seems to be the short-chain
fatty acid with more prominent activity in both reducing IL-6
secretion from LPS-treated U373 cells and upregulation of MAP2
gene in neuroblastoma cells, two other strains, MRx0071 and
MRx1342, known to be butyrate producers (Yuille et al., 2018),
were tested in the same assays conducted above. As expected,
MRx0071 and MRx1342 reduced LPS-induced IL-6 secretion by
U373 cells (Figure 5E) without affecting the redox buffering
capacity toward reactive oxygen of differentiated SH-SY5Y cells
(Figure 5F). Interestingly, even though both MRx0071 and
MRx1342 induced an increase in the fold change of MAP2
gene expression above the media control samples, they did
not reach the significant increase seen following treatment
with MRx0029, thus further supporting the hypothesis that
other metabolites might contribute to the in vitro activity of
MRx0029 (Figure 5G).
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FIGURE 5 | Short-chain fatty acids effect on neuroinflammation and
neuroprotection. U373 cells were treated with increasing concentrations of
Sodium Butyrate (SB, 500 µM–2 mM), Sodium Valerate (SV, 250 µM–1 mM),
or Hexanoic acid (HA, 100–500 µM) in the presence or absence of 1 µg/ml
LPS as reported in section “Materials and Methods.” Cell-free supernatants
were collected 24 h after treatment and secretion of IL-6 (A) and IL-8 (B) were
measured by ELISA. Differentiated SH-SY5Y were treated with 2 mM SB,
0.65 mM SV, and 0.2 mM HA or a combination of the three SCFA at the same
concentration found in 10% BCFS from MRx0029. For ROS evaluation,
(Continued)
FIGURE 5 | Continued
cell treatment in the presence of 100 µM of TBHP for 2 h. Fluorescence
intensity was measured at Ex/Em = 485/530 nm. (D) Undifferentiated cells
were treated with 10% BCFS from MRx0005, MRx0029, MRx0071, and
MRx1342. After 24 h, cells were collected, total RNA isolated for qPCR to
quantify MAP2 gene expression. Data are mean ± SEMSH-SY5Y cells were
treated with 2 mM SB, 0.65 mM SV, 0.2 mM HA or a combination of the three
SCFA as described above. After 24 h, cells were collected, total RNA isolated
for qPCR to quantify MAP2 gene expression. Data are mean ± SEM (n = 3).
(E) U373 cells were treated with 10% BCFS from MRx0071 and MRx1342,
two butyrate-producing strains from 4D pharma culture collection. Cell-free
supernatants were collected 24 h after treatment and secretion of IL-6 was
measured. (F) Differentiated SH-SY5Y cells and were stained with DCFDA
and then treated with 10% BCFS from MRx0005, MRx0029, MRx0071, and
MRx1342 in the presence of TBHP for 2 h, followed by measurement of
fluorescence intensity at Ex/Em = 485/530 nm. (G) Undifferentiated SH-SY5Y
(n = 3).
Evaluation of the Biochemical
Complexity and in vitro Activity of
De-Proteinased MRx0005 and MRx0029
Culture Supernatants
BCFS are complex mixtures of secondary metabolites, including
peptides and proteins. With the aim of further confirming
whether the anti-neuroinflammatory activity of MRx0029 and
MRx0005 activity was mainly due to SCFAs, BCFS were
sequentially extracted with different solvents of increasing
polarity. HPLC analysis of the de-proteinased crude extracts
(hexane, F5; diethyl ether, F4; ethyl acetate, F3; acetonitrile,
F4; methanol, F1) of MRx0005 and MRx0029 supernatants
was conducted to analyse the biochemical complexity of the
stationary phase BCFS of the two strains as well as to
sub-fractionate compounds based on polarity and solubility.
HPLC analysis confirmed the selective extraction and crude
fractionation of compounds present in the de-proteinased
supernatants (data not shown). U373 cells were treated with the
unfractionated BCFS or the different fractions from MRx0005
and MRx0029 both in the presence and absence of LPS. BCFS
were collected 24 h after treatment and analyzed by ELISA for
IL-6 and IL-8 secretion. The methanolic fraction F1 of MRx0029
decreased IL-6 production and appeared to recapitulate the
activity of the unfractionated supernatant, further indicating that
the presence of butyrate is associated with the anti-inflammatory
activity of this strain. The unfractionated MRx0005 supernatant
had a superior effect on IL-6 inhibition compared to the
methanolic fraction F1 of this strain (Figure 6A). The partial
loss of activity might be ascribable both to the removal of a
proteinaceous bioactive component of the supernatant or be
related to the decrease in availability of a compound like succinic
acid due to the chemical processes in place to separate the
different fractions. In the absence of LPS, only the unfractionated
MRx0029 retained its ability to induce IL-6 (Figure 6B). As
expected, unfractionated MRx0029 induced IL-8 secretion in
U373 cells both in the presence and absence of LPS, and the
same activity was produced by the methanolic fraction F1,
thus reiterating the important role of butyric and valeric acid
in IL-8 production by these neuronal cells (Figures 6C,D).
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Moreover, HPLC analysis confirmed the selective extraction
and fractionation of compounds present in the de-proteinased
extracts, as well as corroborated the presence of acetate
and propionate in the methanolic fraction of MRx0005 and
butyrate, valerate and hexanoate in the methanolic fraction of
MRx0029 (Figures 6E,F).
DISCUSSION
Neuroinflammation is a common factor in neurodegenerative
diseases such as Parkinson’s disease (PD) and Alzheimer’s disease
(AD) (Stephenson et al., 2018). Both genetic (e.g., in rare
Mendelian forms of PD and AD) and environmental triggers
(e.g., pollutants, neurotoxic metals) play a pivotal role in inducing
sustained inflammation in different regions of the brain and
in the periphery. Changes in the composition of the human
gut microbiome may contribute to neuroinflammation and have
indicated the importance of the so-called gut-brain axis in disease
setting and progression (Rea et al., 2016). Alterations in gut
barrier permeability are associated with host immune responses
to molecules of gut bacterial origin, such as lipopolysaccharides
(LPS), which are able to reach the systemic circulation and induce
a proinflammatory response (Hayes et al., 2018). Cytokines and
chemokines are involved in the repair of damaged tissues as well
as in the amplification of the proinflammatory response (Charo
and Ransohoff, 2006). Proinflammatory cytokines such as IL-6
and IL-8 have been detected in the serum of PD and AD patients
and correlate with disease progression and decline of cognitive
functions (Reale et al., 2009).
We first investigated the ability of individual members of the
gut microbiome to influence neuroinflammatory processes. For
this purpose, human glioblastoma astrocytoma U373 cells were
treated with LPS, and IL-6 and IL-8 secretion was measured in the
cell supernatants. As we hypothesized that bacterial metabolites
might confer protection in neuroinflammatory processes, we
treated the U373 cells with bacterial supernatants from a
panel of bacterial strains. Out of 50 bacterial supernatants
tested, MRx0005 and MRx0029 showed a remarkable activity in
reducing IL-6 secretion by U373 cells after treatment with LPS.
MRx0005 (P. distasonis) and MRx0029 (M. massiliensis) are
strains from the 4D Pharma culture collection originally isolated
from the fecal samples of healthy human donors which we
have identified as having protective potential. P. distasonis is
an obligately anaerobic Gram-negative, rod-shaped, non-spore
forming and non-motile bacterial species from the Bacteroidetes
phylum (Sakamoto and Benno, 2006). P. distasonis is a common
member of the commensal microbiota in the human intestine and
strains of this species have been studied for their beneficial effects
on Multiple Sclerosis (Cekanaviciute et al., 2017). M. massiliensis
is an obligately anaerobic Gram-negative coccobacillus, which
is non-spore forming, non-motile and is a member of the
Firmicutes phylum (Padmanabhan et al., 2013). Together with
the phylum Bacteroidetes, Firmicutes are a dominant part of the
human gut microbiota (Turnbaugh and Gordon, 2009).
The strong reduction in IL-6 secretion by U373 cells treated
with MRx0005 and MRx0029 cell-free supernatants together
with the intrinsic biotherapeutic potential of these two species
prompted us to further characterize these two strains. U373
cells produced IL-8 in response to LPS. Like IL-6, IL-8 is
a pro-inflammatory cytokine whose presence in the serum is
associated with cognitive dysfunction in the elderly (Baune
et al., 2008). Interestingly, IL-8 can also work as a neurotrophic
factor by promoting survival of hippocampal neuronal cultures
(Araujo and Cotman, 1993). We showed that MRx0005, but not
MRx0029, was able to reduce IL-8 production. This could be of
relevance in relation to the ability of MRx0029 to induce per se
significant levels of IL-8.
As LPS is a ligand for TLR4, a similar experimental setting
was used with the HEK-TLR4 reporter cell line. While both
strains reduced NF-kB activation after treatment with LPS,
only MRx0029 induced NF-kB activation per se, thus further
confirming the observations made in U373 cells. Further work is
needed to understand whether the potency of the response might
be related to different isoforms of LPS or the quantity secreted by
the two strains.
Oxidative stress is associated with cellular neurodegenerative
processes in different regions of the brain (Chen et al.,
2012). As bacteria can produce different antioxidant metabolites
and detoxifying enzymes (Li et al., 2003; Lin et al., 2014),
we evaluated the intrinsic scavenging and total antioxidant
capacity of both strains by measuring the production of
indole, the total radical-trapping antioxidant parameter (TRAP)
and the antioxidant capacity of cell-free supernatants in
relation to Trolox. Overall, MRx0029 showed a superior
antioxidant capacity than MRx0005. However, only MRx0005
conferred protection from reactive oxygen species (ROS) in
glioblastoma U373 cells and microglia HMC3 cells. Interestingly,
differentiated neuroblastoma SH-SY5Y cells treated with cell-
free supernatants showed that MRx0029 was as good as
MRx0005 in protecting these cells from TBHP toxicity,
suggesting a surprisingly specific tropism of MRx0029 for
neuron-like cells.
Differentiated SH-SY5Y cells recapitulate many of the
biochemical and functional properties of neurons (Agholme
et al., 2010; Forster et al., 2016) and are a commonly
used model for NDDs. When undifferentiated SH-SY5Y
cells were treated with cell-free supernatants from MRx0005
and MRx0029, microscopic examination revealed that SH-
SY5Y cells treated with MRx0029 resembled a neuron-like
phenotype, with multiple elongated processes on an oblong
body. Gene expression of markers distinctive for differentiated
neurons, such as microtubule-associated protein 2 (MAP2)
and synaptophysin (SYP), indeed confirmed that MRx0029
induced a differentiated phenotype in neuroblastoma cells.
MAP2 upregulation was observed both at gene and protein
levels. Further, immunofluorescent labeling revealed that MAP2
localized in the neurites and dendrites as well as in perikarya of
mature neurons (Tanapat, 2013). Phalloidin staining indicated
a mature neuron-like rearrangement of the cytoskeleton, so
we investigated the expression and staining pattern of β3-
tubulin, another neurogenesis-associated differentiation marker
which plays a role in neuron-specific intracellular structural and
transport processes (Pellegrini et al., 2017). Once again, MRx0029
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FIGURE 6 | Biochemical characterization and in vitro evaluation of the biological activity of MRx0005 and MRx0029 culture supernatant fractions. BCFS from three
biological replicates from MRx0005 and MRx0029 were mixed with different solvents of increasing polarity and extracts used in cell-based assays. 10% BCFS,
media alone, five different fractions and blank media treated with the same solvents used to prepare the fractions were added to U373 cells in the presence or
absence of LPS as described in section “Materials and Methods.” Cell-free supernatants were collected 24 h after treatment and secretion of IL-6 and IL-8 was
measured by ELISA. IL-6 secretion measured in U373 cells (A) pre-treated with 1 µg/ml LPS or in the absence of LPS (B); IL-8 secretion measured in U373 cells (C)
pre-treated with 1 µg/ml LPS or in the absence of LPS (D). (E,F) The MeOH fractions from MRx0005 and MRx0029 were analyzed by HPLC for SCFAs band
MCFAs. Representative examples of HPLC chromatograms are shown for MRx0005 and MRx0029. The methanolic fractions for MRx0005 (E) and MRx0029 (F)
were extracted for SCFAs and MCFAs and then overlaid to a standard mix of SCFAs and MCFAs (Formic acid 10 mM, Acetic acid 20 mM, Propionic acid 10 mM,
Butyric acid 10 mM, Valeric acid 10 mM, and Hexanoic acid 10 mM in black). The chromatograms highlight the lack of butyric, valeric and hexanoic acid in the
MRx0005 methanolic fraction and their presence in the MRx0029 methanolic fraction.
but not MRx0005 induced an upregulation at protein level of
β3-tubulin, albeit not to a significant level.
The tandem increase of protein expression of β3-tubulin and
more importantly of MAP2 by MRx0029 further strengthens our
hypothesis of a tropism of MRx0029 toward a mature phenotype,
suggesting that MRx0029 metabolites might alter microtubule
dynamics in neuron-like cells. Moreover, as MAP2 promotes
neurite outgrowth, which play a major role in re-networking of
damaged neurons and synaptogenesis, MAP2 expression might
go beyond being a marker of neuronal differentiation and
indicate “neuronal re-wiring” associated with the therapeutic
outcome of neuropathological disease (Abdanipour et al., 2015).
Overall, we have demonstrated that MRx0005 and MRx0029
affect host function differently in different types of brain cells,
with distinct effects on inflammation and neuronal cells. The
caveat here is that the cells we have used in this study are either
immortalized or derived from tumors. This choice was made to
assure a reproducibility of the data at this stage of the project.
More investigation using primary microglia cells and neurons
are undoubtedly necessary and planned to further understand the
biological meaning behind our findings.
We postulate that the effects observed on neuroinflammation
and oxidative stress are mediated by bacterial production of
different classes of metabolites. SCFAs produced by gut bacteria
are typically recognized as positive modulators of host functions.
SCFAs mediate water and sodium intake by epithelial cells
and play an important role in the proliferation, differentiation
and regulation of epithelial cells (Wang et al., 2019). For
Frontiers in Cellular Neuroscience | www.frontiersin.org 14 September 2019 | Volume 13 | Article 402
fncel-13-00402 September 19, 2019 Time: 10:16 # 15
Ahmed et al. Neuroprotection by Gut Microbiota-Derived Bacterial Strains
example, propionate and butyrate participate in the preservation
of mucosal integrity, thwart the proliferation of pathogens in
the gut and have been shown to modulate energy metabolism
through the gut-brain axis (den Besten et al., 2013; van der
Beek et al., 2017; Li et al., 2018). Valeric acid interferes with
β-amyloid peptides 1-40 and 1-42 fibril formation in vitro
and prevents α-synuclein monomers from pairing up and
aggregating into fibrils (Ho et al., 2018). Hexanoic acid has been
shown to reduce the colonization and dysbiotic expansion of
potentially pathogenic bacteria in the gut (Van Immerseel et al.,
2004). Succinic acid plays a neuroprotective role in oxidative
phosphorylation, a key step for synaptic trafficking of proteins
to proximal and distal regions (Budd and Nicholls, 1998). It
also augments mitochondrial activity and together with BDNF
supports vulnerable neurons in neurodegenerative disorders
(Ferro et al., 2017).
MRx0029 is a strong producer of butyric, valeric and hexanoic
acid and we investigated the ability of these SCFAs to decrease
neuroinflammation in glioblastoma cells and oxidative stress
in neuron-like cells. They were tested as single SCFAs and in
combination at the same concentrations present in the cell-
free supernatant. Interestingly, only butyric acid was able to
reduce IL-6 secretion in the presence of LPS in a concentration-
dependent manner. Neither valeric nor hexanoic acid inhibited
IL-6 or IL-8 secretion in the presence of LPS. The combination
of the three SCFAs reconstituted at the same concentration
measured in MRx0029 supernatant recapitulated the activity
of the supernatant, suggesting that butyrate drove the anti-
inflammatory activity of MRx0029. However, butyrate and valeric
acid were only partially involved in the ability of MRx0029 to
induce a mature phenotype in neuroblastoma cells. It has been
reported that medium-chain fatty acids can promote neurite
outgrowth (Kamata et al., 2007).
To simplify the complexity of the supernatant and assess the
activity of the SCFAs, the cell-free supernatants from MRx0005
and MRx0029 were extracted with solvents of increasing polarity.
Only the methanolic fraction of MRx0029 containing butyric,
valeric and hexanoic acid produced the same effects on U373 cells
as described above. Of note, the methanolic fraction of MRx0005
containing acetate and propionate only partially recapitulated
the anti-inflammatory activity of MRx0005, which might be due
to the removal of proteinaceous bioactive molecules or to the
chemical treatment resulting in the potential generation of esters
of fatty acids such as succinate. Our theory is that is the synergistic
activity of SCFAs and other metabolites produced by MRx0029
creates the neurotrophic activity of this strain and supports its
potential therapeutic use as an LPB in the treatment of NDDs.
MRx0029 is a histone deacetylase (HDAC) inhibitor through
its production of butyrate, as shown in a research paper recently
published by our group (Yuille et al., 2018). Wakade and Chong
investigated the neuroprotective mechanisms of butyric acid in
the context of Parkinson’s disease by analyzing the relationship
between the niacin receptor and dopamine levels (Wakade and
Chong, 2014). Butyric acid has the potential to beneficially impact
Parkinson’s symptoms by reducing inflammation, increasing
dopamine synthesis (by improving the amount of free niacin that
is available for dopamine synthesis) and boosting mitochondrial
function to provide cells with more energy (Donohoe et al., 2011;
Bourassa et al., 2016). Our findings highlight how the activity
of a specific combination of SCFAs can affect neuropathological
aspects of NDDs and how the use of LBPs rather than the single
purified metabolite could be therapeutically successful.
In summary, this study provides compelling evidence of
how using our in vitro screening platform we have identified
two gut-derived bacteria that can modulate relevant cell types
targeted by neuroinflammation and oxidative stress in NDDs.
The strains P. distasonis MRx0005 and M. massiliensis MRx0029
both have an anti-inflammatory signature, however, MRx0029
seems to preferentially protect neurons from cytotoxicity induced
by oxidative stress. More investigations using relevant in vitro
and in vivo models are underway to fully dissect the molecular
pathways behind the therapeutic use of these bacteria strains in
neurodegenerative diseases.
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